Tesamorelin
Effect Profile
How Tesamorelin scores across 8 body systems
24
/ 80 total
Top strengths
Purrptide digest
Tesamorelin has actual FDA approval — for reducing visceral fat in HIV patients with lipodystrophy. That's a narrow lane, but it's a real, regulated lane. The interesting part: it specifically targets visceral fat, the dangerous kind wrapped around your organs, more than subcutaneous fat. Most fat-loss drugs aren't that picky. Longevity clinics took notice and started prescribing it off-label well outside the original HIV indication, betting that visceral-fat-specific targeting matters for everyone, not just one patient population.
What this means for you
If visceral fat (the kind around your organs) is your specific concern, this is one of the few peptides with FDA-grade evidence targeting exactly that.
Actually FDA-approved, which is rare on this list. The off-label expansion beyond HIV lipodystrophy is the part to watch.
Selective visceral fat reduction without proportional subcutaneous fat loss is mechanistically distinct and underexplored outside the HIV population.
An approved drug with an expanding off-label market is the easiest commercial story in this entire list.
For the nerds
Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients
JAMA · DOI: 10.1001/jama.2014.12399
Read full paper on PubMed →